Enveric Biosciences

About Enveric Biosciences

Enveric Biosciences is a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics for treating neuropsychiatric disorders. Using its unique discovery and development platform, The Psybrary™, Enveric aims to address mental health challenges through innovative solutions.

Products & Services

EB-003:A therapeutic targeting difficult-to-treat mental health disorders under a prescription model, with the next milestone being a Pre-IND FDA meeting (40% progress).

EVM401:A therapeutic in the discovery phase focused on mental health and addiction (15% progress).

Psybrary™:A unique discovery and development platform for creating novel molecules for specific mental health indications.

Specialties

Neuroplastogenic therapeutics Neuropsychiatric disorders Mental health treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1500000 MR: - FA: $1.5 million FAN: 1500000	D: 2026-01-28 FD: 2026-01-28	-
2	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 3100000 MR: - FA: 3.1 million FAN: 3100000	D: 2025-12-12 FD: 2025-12-12	1 investors
3	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 3100000 MR: - FA: approximately $3.1 million FAN: 3100000	D: 2025-12-11 FD: 2025-12-11	-
4	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 2200000 MR: - FA: 2.2 million FAN: 2200000	D: 2025-09-18 FD: 2025-09-18	1 investors
5	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 2200000 MR: - FA: 2.2 million FAN: 2200000	D: 2025-09-17 FD: 2025-09-17	-
6	RT: Public Offering T: - FT: Public Offering	A: 5000000 MR: - FA: approximately $5 million FAN: 5000000	D: 2025-02-03 FD: 2025-02-03	-
7	RT: Public Offering T: - FT: Public Offering	A: 5000000 MR: - FA: $5 Million FAN: 5000000	D: 2025-01-30 FD: 2025-01-30	-
8	RT: Private Placement T: - FT: Private Placement	A: 1800000 MR: - FA: approximately $1.8 million FAN: 1800000	D: 2023-12-29 FD: 2023-12-29	-

Registered Direct Offering Latest

2026-01-28

$1.5M

Warrant Exercise 2025-12-12

$3.1M

Warrant Exercise 2025-12-11

$3.1M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Joseph Tucker

Chief Executive Officer, Director

P

Peter Facchini

PhD, Faculty of Graduate Studies

K

Kevin Coveney

Chief Financial Officer

J

Jillian Hagel

Vice President, Innovation

M

Michael D. Webb

Board Chair

G

George Kegler

Director, Chair of the Audit Committee

View 10 more team members with Pro

Unlock Full Team Directory

Recent News